For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ImmunityBio Inc (NASDAQ: IBRX) closed the day trading at $2.87 down -5.59% from the previous closing price of $3.04. In other words, the price has decreased by -$5.59 from its previous closing price. On the day, 8.82 million shares were traded. IBRX stock price reached its highest trading level at $3.12 during the session, while it also had its lowest trading level at $2.815.
Ratios:
For a better understanding of IBRX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.64 and its Current Ratio is at 2.68.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Piper Sandler on May 12, 2023, Downgraded its rating to Neutral and sets its target price to $4 from $10 previously.
On August 03, 2022, Jefferies started tracking the stock assigning a Buy rating and target price of $8.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IBRX now has a Market Capitalization of 2095573504 and an Enterprise Value of 2889256704. For the stock, the TTM Price-to-Sale (P/S) ratio is 257.58. Its current Enterprise Value per Revenue stands at 394.061 whereas that against EBITDA is -8.465.
Stock Price History:
Over the past 52 weeks, IBRX has reached a high of $10.53, while it has fallen to a 52-week low of $2.97. The 50-Day Moving Average of the stock is -36.56%, while the 200-Day Moving Average is calculated to be -45.55%.
Shares Statistics:
Over the past 3-months, IBRX traded about 5.68M shares per day on average, while over the past 10 days, IBRX traded about 7145350 shares per day. A total of 696.83M shares are outstanding, with a floating share count of 159.81M. Insiders hold about 77.07% of the company’s shares, while institutions hold 9.89% stake in the company. Shares short for IBRX as of 1732838400 were 49778598 with a Short Ratio of 8.76, compared to 1730332800 on 52749830. Therefore, it implies a Short% of Shares Outstanding of 49778598 and a Short% of Float of 30.8.
Earnings Estimates
The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0. EPS for the following year is -$0.42, with 1 analysts recommending between -$0.42 and -$0.42.
Revenue Estimates
1 analysts predict $9.07M in revenue for the current quarter. It ranges from a high estimate of $9.07M to a low estimate of $9.07M. As of the current estimate, ImmunityBio Inc’s year-ago sales were $139kFor the next quarter, 1 analysts are estimating revenue of $20.02M. There is a high estimate of $20.02M for the next quarter, whereas the lowest estimate is $20.02M.
A total of 3 analysts have provided revenue estimates for IBRX’s current fiscal year. The highest revenue estimate was $39.9M, while the lowest revenue estimate was $15.6M, resulting in an average revenue estimate of $23.92M. In the same quarter a year ago, actual revenue was $622kBased on 3 analysts’ estimates, the company’s revenue will be $138.17M in the next fiscal year. The high estimate is $170.8M and the low estimate is $113.6M.
